Navigation Links
EDC Functionality, Ease of Data Entry, and Access to Data All Factors in University of Virginia Cancer Center's Selection of the OnCore Clinical Research Management System
Date:1/11/2011

xecution (RPE) data exchange standard being put forth by the Integrating the Healthcare Enterprise (IHE) initiative.

"Our future vision includes transparent communication of data between our clinical EMR, our research data repository, and OnCore. Thus, we expect to manage patients in the clinical setting using the EMR, with information about protocols flowing transparently to both the EMR and the clinical data repository from OnCore, and information about subjects and research visit data flowing transparently from the EMR and the clinical data repository to OnCore without redundant entry," said Fracasso.

Ultimately, the Cancer Center is interested in using the OnCore system for project budgeting, and for billing for all patients on clinical trials.

About the UVA Cancer Center

At the UVA Cancer Center we don't just treat diseases. We treat whole persons and entire families. We do this through a unique disease-specific team approach to care, and an array of services for those who encounter one of life's greatest struggles - a battle against cancer.  

As a "National Cancer Institute Designated Cancer Center," the Cancer Center's goal is to deliver cutting edge cancer care, and to create that cutting edge with novel research. Leading programs in clinical and discovery research are supported by over $70 million a year from the National Institutes of Health, the National Cancer Institute, the American Cancer Society, and other agencies. Additionally, the Cancer Center receives philanthropy from friends and grateful patients that supports our mission. Over 150 basic scientists and clinical researchers are involved in cancer research, and there are more than 75 interventional clinical trials actively accruing patients to test new therapies.

About OnCore

The OnCore platform is the flagship product from Forte Research Systems, Inc., a software development company specializing in clinical and translational re
'/>"/>

SOURCE Forte Research Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... valves and hemodynamic monitoring, today announced that Robert A. ... "Bob is an ardent champion for innovation in ... to have him on Edwards, board as we pursue our ... chairman and CEO.  "Bob has provided a valuable perspective to ...
(Date:7/30/2015)... July 30, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin ... non-exclusive Development Agreements with Dexcom, Inc. to allow ... with the Dexcom G5 and G6 continuous glucose ... generation pump platform with Dexcom,s future CGM systems ...
(Date:7/30/2015)... THOUSAND OAKS, Calif., July 30, 2015  Amgen ... for the second quarter of 2015. Key results ... versus the second quarter of 2014 to $5,370 ... primarily by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23
... ANTIPOLIS, France, May 11, 2007 /PRNewswire-FirstCall/ --,NicOx S.A. ... phase 2a,study for NCX 1000, which is covered ... A preliminary analysis of 11 patients,from this proof-of-concept ... NCX 1000 but did not demonstrate the efficacy,required ...
... 2007--Sciele Pharma, Inc.,(NASDAQ:SCRX) today announced the successful completion ... formulation. The study,results showed that the new Sular ... new Sular formulation,utilizes SkyePharma's (LSE:SKP) patented Geomatrix technology,which ... Sular for each of its,current doses. , The ...
Cached Medicine Technology:NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 2Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 3Sciele Pharma Announces Successful Completion of New Sular,Formulation Clinical Trial Program 4
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s ... It was also the first provider of Exilis non-surgical fat reduction in New York. ... it has attracted a large International clientele. Many patients travel to New York ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical ... PRO this week. Zeltiq Aesthetics released this new applicator in the United States ... for treating the outer thighs. The original applicator required a 2 hour treatment ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Coco Libre announced ... judges, media, and VIPs at the 2015 Vans US Open of Surfing, July 25 ... that can claim “no added sugar” on the market, is a natural choice given ...
(Date:7/31/2015)... ... , ... According to an article published July 2 on Healio, ... a consensus on the steps that need to be taken to successfully complete several ... consensus on a series of steps that each surgeon must complete for each procedure. ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... has joined the,MassMutual Retirement Services Division,s institutional sales ... is based in Texas,and supports MassMutual,s third party ... He joins MassMutual from John Hancock where he ... company,s retirement plan services,business. Ambrose has more than ...
... must be at play to raise women,s risk, researchers say ... to hike the risk of cardiovascular disease, but don,t put ... So concludes a study led by Dr. Viola Vaccarino, a ... means that it,s back to the drawing board in terms ...
... November, 2007 Reproductive Health Matters and Elsevier are pleased ... the celebration of the twentieth anniversary of the Safe Motherhood ... November issue responds to the question Is Pregnancy Getting ... no. , Globally, the maternal mortality ...
... ... Diabetes Day, MARLBOROUGH, Mass., ... medical technology company for the design,development, manufacturing and marketing of retinal ... 2007. On this,one day over 100 eye care practices throughout North ...
... Nov. 15 Every year more,holiday shoppers look ... above the rest while helping families in need. ... taken this,charitable holiday gift-giving approach to heart offering ... . Mercy Kits give people the opportunity ...
... have to get into a,cold bed again with an ... too heated up by all of the choices available. ... are more options to choose from than ever before,",according ... http://www.comforthouse.com ). Gornstein evaluates dozens of new electric,blankets and ...
Cached Medicine News:Health News:Inflammation Can't Explain Depression's Link to Heart Disease 2Health News:November issue of Reproductive Health Matters focuses on maternal mortality 2Health News:Free Diabetes Eye Screenings Taking Place in Recognition of World Diabetes Day 2Health News:Online Charitable Holiday Giving: Making a Difference with the Gifts You Give 2Health News:What's New in Electric Blankets and Heated Mattress Pads 2
... standard in corneal diagnostics. Precise Display ... membrane, stroma, Bowman's membrane and epithelial ... Broad Applications in Surgery and Pathology. ... evaluation, endothelial cell analysis, haze detection, ...
... appearance of photo-aged skin, removes age spots ... and broken capillaries. This innovative new application ... pigmentary sun damage through a process called ... and the Nd:YAG Laser is optimized for ...
... affordable lenses available in a variety ... available in prescription powers for those ... "Plano" for those who don't. They ... technology. Incredibly comfortable, 10 fun, eye-catching ...
Each jet black lens features a mesmerizing thin white line that spirals toward the center of the pupil....
Medicine Products: